|
1
|
Fan W and Du J: Nasal polyps associated
with nasopharyngeal carcinoma in child: One case report and review.
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 27:273–274.
2013.(In Chinese). PubMed/NCBI
|
|
2
|
Colaco RJ, Betts G, Donne A, Swindell R,
Yap BK, Sykes AJ, Slevin NJ, Homer JJ and Lee LW: Nasopharyngeal
carcinoma: A retrospective review of demographics, treatment and
patient outcome in a single centre. Clin Oncol (R Coll Radiol).
25:171–177. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsang CM and Tsao SW: The role of
Epstein-Barr virus infection in the pathogenesis of nasopharyngeal
carcinoma. Virol Sin. 30:107–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dawson CW, Port RJ and Young LS: The role
of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the
pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol.
22:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Strazzulla A, Barreca GS, Giancotti A,
Pisani V, Costa C, Zicca E, La Boria A, Roveda L, Liberto MC, Tucci
L, et al: Nasopharyngeal carcinoma: Review of the literature with a
focus on therapeutical implications. Infez Med. 23:224–229.
2015.PubMed/NCBI
|
|
6
|
Gioacchini FM, Tulli M, Kaleci S, Magliulo
G and Re M: Prognostic aspects in the treatment of juvenile
nasopharyngeal carcinoma: A systematic review. Eur Arch
Otorhinolaryngol. 274:1205–1214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiao W, He Z, Xing C, Zhen W, Wang S and
Lin H: Clinicopathologic features and treatment of breast
metastasis from nasopharyngeal carcinoma: A report of two cases and
literature review. Oncol Lett. 10:3675–3681. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Setton J, Wolden S, Caria N and Lee N:
Definitive treatment of metastatic nasopharyngeal carcinoma: Report
of 5 cases with review of literature. Head Neck. 34:753–757. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Caponigro F, Longo F, Ionna F and Perri F:
Treatment approaches to nasopharyngeal carcinoma: A review.
Anticancer Drugs. 21:471–477. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yeo CD, Lee SH, Kim JS, Kim SJ, Kim SC,
Kim YK, Kang HH, Yoon HK, Song JS, Moon HS, et al: A multicenter
phase II study of belotecan, a new camptothecin analogue, in
elderly patients with previously untreated, extensive-stage small
cell lung cancer. Cancer Chemother Pharmacol. 72:809–814. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arakawa Y, Ozaki K, Okawa Y and Yamada H:
Three missense mutations of DNA topoisomerase I in highly
camptothecin-resistant colon cancer cell sublines. Oncol Rep.
30:1053–1058. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bertozzi D, Marinello J, Manzo SG, Fornari
F, Gramantieri L and Capranico G: The natural inhibitor of DNA
topoisomerase I, camptothecin, modulates HIF-1α activity by
changing miR expression patterns in human cancer cells. Mol Cancer
Ther. 13:239–248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Veloso A, Biewen B, Paulsen MT, Berg N, de
Andrade Lima Carmo L, Prasad J, Bedi K, Magnuson B, Wilson TE and
Ljungman M: Genome-wide transcriptional effects of the anti-cancer
agent camptothecin. PLoS One. 8:e781902013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee M, Kim Young S, Kim J, Kim HS, Kim SM
and Kim EJ: Mitogen-activated protein kinase phosphatase-1
inhibition and sustained extracellular signal-regulated kinase 1/2
activation in camptothecin-induced human colon cancer cell death.
Cancer Biol Ther. 14:1007–1015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun LC, Luo J, Mackey LV, Fuselier JA and
Coy DH: A conjugate of camptothecin and a somatostatin analog
against prostate cancer cell invasion via a possible signaling
pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/−9.
Cancer Lett. 246:157–166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gaur S, Wang Y, Kretzner L, Chen L, Yen T,
Wu X, Yuan YC, Davis M and Yen Y: Pharmacodynamic and
pharmacogenomic study of the nanoparticle conjugate of camptothecin
CRLX101 for the treatment of cancer. Nanomedicin. 10:1477–1486.
2014. View Article : Google Scholar
|
|
17
|
Tang Q, Ji F, Guo J, Wang J, Li Y and Bao
Y: Directional modification of chrysin for exerting apoptosis and
enhancing significantly anti-cancer effects of 10-hydroxy
camptothecin. Biomed Pharmacother. 82:693–703. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Su H, Zhang P, Cheetham AG, Koo JM, Lin R,
Masood A, Schiapparelli P, Quiñones-Hinojosa A and Cui H:
Supramolecular crafting of self-assembling camptothecin prodrugs
with enhanced efficacy against primary cancer cells. Theranostics.
6:1065–1074. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Artyukhin AA: Plastic repair of the
deferent duct with a silicone tubular prosthesis under conditions
of a chronic experiment on laboratory animals. Bull Exp Biol Med.
144:91–95. 2007.(In English, Russian). View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Renshaw A and Elsheikh TM: A validation
study of the Focalpoint GS imaging system for gynecologic cytology
screening. Cancer Cytopathol. 121:737–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bai FL, Yu YH, Tian H, Ren GP, Wang H,
Zhou B, Han XH, Yu QZ and Li DS: Genetically engineered Newcastle
disease virus expressing interleukin-2 and TNF-related
apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther.
15:1226–1238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Turki S, Mardassi A, Abouda M, Hachicha A
and Ben Jallel W: Orbital metastasis revealing an undifferenciated
Carcinoma of nasopharyngeal type: A case report. Tunis Med.
94:148–151. 2016.PubMed/NCBI
|
|
23
|
Genova P, Brunetti F, Bequignon E, Landi
F, Lizzi V, Esposito F, Charpy C, Calderaro J, Azoulay D and
de'Angelis N: Solitary splenic metastasis from nasopharyngeal
carcinoma: A case report and systematic review of the literature.
World J Surg Oncol. 14:1842016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding X, Matsuo K, Xu L, Yang J and Zheng
L: Optimized combinations of bortezomib, camptothecin, and
doxorubicin show increased efficacy and reduced toxicity in
treating oral cancer. Anticancer Drugs. 26:547–554. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chazin Ede L, Reis Rda R, Junior WT, Moor
LF and Vasconcelos TR: An overview on the development of new
potentially active camptothecin analogs against cancer. Mini Rev
Med Chem. 14:953–962. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang LF, Li YH, Xie SH, Ling W, Chen SH,
Liu Q, Huang QH and Cao SM: Incidence trend of nasopharyngeal
carcinoma from 1987 to 2011 in Sihui County, Guangdong Province,
South China: An age-period-cohort analysis. Chin J Cancer.
34:350–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu S, Wang X, Shu J, Zhao Z, Sun Z and
Luo B: Sequence analysis of EBV immune evasion gene BNLF2a in EBV
associated tumors and healthy individuals from nasopharyngeal
carcinoma endemic and non-endemic regions of China. J Med Virol.
87:1946–1952. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tian W, Zhu FM, Wang WY, Cai JH, Zhang W,
Li LX, Liu KL, Jin HK and Wang F: Sequence-based typing of HLA-A
gene in 930 patients with nasopharyngeal carcinoma in Hunan
province, southern China. Tissue Antigens. 86:15–20. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hamilton G, Klameth L, Rath B and
Thalhammer T: Synergism of cyclin-dependent kinase inhibitors with
camptothecin derivatives in small cell lung cancer cell lines.
Molecules. 19:2077–2088. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mollica A, Stefanucci A, Feliciani F,
Cacciatore I, Cornacchia C and Pinnen F: Delivery methods of
camptothecin and its hydrosoluble analogue irinotecan for treatment
of colorectal cancer. Curr Drug Deliv. 9:122–131. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu Z, Zheng Q, Chen W, Wu M, Pan G, Yang
K, Li X, Man S, Teng Y, Yu P and Gao W: Chemosensitizing effect of
Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung
cancer cells via p38 MAPK, ERK, and Akt signaling pathways. Eur J
Med Chem. 125:760–769. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park ES, Kang SI, Yoo KD, Lee MY, Yoo HS,
Hong JT, Shin HS, Kim B and Yun YP: Camptothecin inhibits
platelet-derived growth factor-BB-induced proliferation of rat
aortic vascular smooth muscle cells through inhibition of PI3K/Akt
signaling pathway. Exp Cell Res. 319:982–991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jayasooriya RG, Park SR, Choi YH, Hyun JW,
Chang WY and Kim GY: Camptothecin suppresses expression of matrix
metalloproteinase-9 and vascular endothelial growth factor in DU145
cells through PI3K/Akt-mediated inhibition of NF-κB activity and
Nrf2-dependent induction of HO-1 expression. Environ Toxicol
Pharmacol. 39:1189–1198. 2015. View Article : Google Scholar : PubMed/NCBI
|
